Afamelanotide

Pharmaceutical-Grade

Afamelanotide is a 13-amino acid linear peptide (sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2) that is a superpotent analog of the endogenous melanocortin peptide alpha-MSH ([Nle4, D-Phe7]-alpha-MSH, also known as NDP-alpha-MSH or NDP-MSH). The key structural modifications — substitution of methionine-4 with norleucine (Nle) and L-phenylalanine-7 with D-phenylalanine (D-Phe) — dramatically enhance binding affinity and metabolic stability compared to native alpha-MSH, producing a long-acting MC1R agonist with approximately 100-fold greater potency. Upon subcutaneous implantation, afamelanotide is slowly released from its biodegradable poly(DL-lactide-co-glycolide) implant over approximately 10 days, activating melanocortin 1 receptors (MC1R) on epidermal melanocytes and stimulating the production of eumelanin — the brown-black pigment that provides the most effective UV photoprotection. Erythropoietic protoporphyria (EPP) is a rare genetic disorder caused by deficient ferrochelatase enzyme activity, leading to accumulation of protoporphyrin IX in erythrocytes, plasma, and skin. Upon exposure to visible light (primarily 400–410 nm wavelength), protoporphyrin IX undergoes photoactivation, generating reactive oxygen species and singlet oxygen that cause severe endothelial damage, mast cell degranulation, and excruciating neuropathic-like pain — often described by patients as burning from the inside. Conventional sunscreens are ineffective because EPP phototoxicity is triggered by visible light, not UV radiation. Afamelanotide addresses this by increasing eumelanin content in the skin, which absorbs across a broad spectrum including visible wavelengths, providing a measure of photoprotection. In pivotal clinical trials (CUV039 in Europe and CUV040 in the US), patients receiving afamelanotide implants every 60 days experienced significantly more time outdoors in direct sunlight without pain (median increase of approximately 70 hours over 180 days vs. placebo), reduced severity of phototoxic reactions, and improved quality of life scores. The implant is administered by a healthcare professional via a subcutaneous injection procedure every 2 months, with the most common adverse effects being implant site reactions, headache, and nausea.